Occurrence of malignant neoplasia in patients with primary hyperparathyroidism by S. Palmieri et al.
For Review Only
 
 
 
Occurrence of malignant neoplasia in patients with primary 
hyperparathyroidism 
 
 
Journal: European Journal of Endocrinology 
Manuscript ID EJE-17-0028 
mstype: Clinical Study  
Date Submitted by the Author: 13-Jan-2017 
Complete List of Authors: Palmieri, Serena; Ospedale Maggiore Policlinico, Unit of Endocrinology and 
Metabolic Diseases; Universita degli Studi di Milano, Department of Clinical 
Sciences and Community Health 
Roggero, Letizia; Universita degli Studi di Milano, Dpt. of Medical Sciences 
and Community Health; Ospedale Maggiore Policlinico, Unit of 
Endocrinology and Metabolic Diseases 
Cairoli, Elisa; Universita degli Studi di Milano, Dpt. of Medical Sciences and 
Community Health; Ospedale Maggiore Policlinico, Unit of Endocrinology 
and Metabolic Diseases 
Morelli, Valentina; Universita degli Studi di Milano, Dpt. of Medical Sciences 
and Community Health; Ospedale Maggiore Policlinico, Unit of 
Endocrinology and Metabolic Diseases 
Scillitani, Alfredo; Casa Sollievo della Sofferenza Scientific Institute, Unit of 
Endocrinology 
Chiodini, Iacopo; Ospedale Maggiore Policlinico, Unit of Endocrinology and 
Metabolic Diseases 
Eller-Vainicher, Cristina; Ospedale Maggiore Policlinico, Unit of 
Endocrinology and Metabolic Diseases 
Keywords: Primary hyperparathyroidism, malignancy, breast cancer, vitamin D 
  
 
 
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
1 
 
Occurrence of malignant neoplasia in patients with primary hyperparathyroidism 1 
Serena Palmieri1,2, Letizia Roggero1, Elisa Cairoli1,2, Valentina Morelli1,2, Alfredo Scillitani3,                 2 
Iacopo Chiodini2, Cristina Eller-Vainicher2. 3 
 4 
1Department of Medical Sciences and Community Health, University of Milan, Milan, Italy. 5 
2Unit of Endocrinology and Metabolic Diseases, IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, 6 
Italy. 
 3
Unit of Endocrinology, “Casa Sollievo della Sofferenza”, Hospital, IRCCS, San Giovanni Rotondo, 7 
Foggia, Italy. 8 
Short title: Cancer and primary hyperparathyroidism 9 
Keywords: Primary hyperparathyroidism, malignancy, breast cancer, vitamin D 10 
Word count: 3284 11 
Number of figures/tables: 2/3  12 
Disclosure Summary: Authors have nothing to disclose. 13 
Corresponding author and person to whom the reprint request should be addressed: 14 
Iacopo Chiodini, MD 15 
Unit of Endocrinology and Metabolic Diseases, Padiglione Granelli,  16 
Fondazione IRCCS Cà-Granda, Ospedale Maggiore Policlinico 17 
Via Francesco Sforza 35, 20122 Milan, Italy.  18 
Phone : +39-2-55033355 ; Fax : +39-2-50320605; e-mail: iacopo.chiodini@unimi.it  19 
Page 1 of 22
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
2 
 
Abstract 20 
Background. The association between primary hyperparathyroidism (1HPT) and cancer is debated. The 21 
present study was aimed to investigate the occurrence of neoplasia in 1HPT.  22 
Methods: All consecutive patients (n=1750) referred to our “Osteoporosis and Metabolic Disease” 23 
outpatients clinic for osteoporosis or hypercalcemia were eligible for the study. The exclusion criteria were: 24 
the finding of osteoporosis and/or altered calcium-phosphorous metabolism in the context of investigations 25 
for malignancy, the presence of diseases known to influence the cancer risk and the heavy smoking habit. 26 
Eventually, 1606 patients (1407 females, 199 males) were enrolled. In all patients calcium-phosphorous 27 
metabolism, PTH and vitamin D levels were measured and the occurrence of cancer during the 10 years prior 28 
the study inclusion was recorded. 29 
Results: 163 patients had 1HPT while 1443 had not. Patients with and without 1HPT were comparable for 30 
age and gender.  In 1HPT patients the occurrence of all, breast, kidney and skin cancer was significantly 31 
higher (21.5%, 12.2%, 2.5%, 1.8%, respectively) than in patients without 1HPT (12.4%, 6.9%, 0.3%, 0.3%, 32 
p<0.05 for all comparisons). The 1HPT presence was significantly associated with the occurrence of all 33 
neoplasia and of breast, skin and kidney neoplasia (odds ratio, 95% confidence interval, P value: 1.93, 1.27-34 
2.92, 0.002; 1.93, 1.11-3.35, 0.002; 9.18, 2.16-38.8, 0.003; 8.23, 1.71-39.5, 0.008, respectively), after 35 
adjusting for age, gender (as appropriate), smoking habit and vitamin D levels. 36 
Conclusions: During the 10 years prior the diagnosis of 1HPT, the occurrence of all, breast, skin and kidney 37 
neoplasia is increased.  38 
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Introduction 39 
Primary hyperparathyroidism (1HPT) affects at least 1 in 1000 persons and its incidence rises with 40 
age, with a peak in the seventh decade (1, 2). The 1HPT risk is 5-fold higher in women than in men after 75 41 
years of age, while it is comparable between sexes before 45 years of age (1).  In the majority (i.e. 80-85%) 42 
of cases 1HPT is due to a single gland adenoma, with hyperplasia and parathyroid carcinoma accounting for 43 
the 10-15% and <1% of cases, respectively (2). 44 
The 1HPT condition is characterized by hypercalcemia, increased urinary calcium excretion and 45 
inappropriately high or unsuppressed levels parathyroid hormone (3), and it may lead to osteoporosis, 46 
fragility fractures and kidney stones and, possibly, to an increased risk of cardiovascular events and neuro-47 
psychological alterations (4). Besides these consequences, given the evidence of an increased cancer-related 48 
mortality in 1HPT (5, 6) and of the possible anti-apoptotic action of the parathyroid hormone (PTH) (7-9), in 49 
the past years some authors investigated the possibility of an increased risk of malignancies in this condition 50 
(5, 6, 10-18). Interestingly, cancer is now a known feature of chronic kidney disease, which is characterized 51 
persistently elevated PTH values (19).  52 
However, while some studies found an increased risk of some malignancies, such as  breast, skin, 53 
colon, thyroid and kidney cancer (10-16), other investigations were not able to find any association between 54 
1HPT and malignant neoplasia (17, 18). These discordances are probably due to the different designs (i.e. 55 
retrospective or prospective), different settings (i.e. national registers- or population-based) and different 56 
inclusion criteria (i.e. all patients diagnosed with 1HPT or only surgically treated 1HPT patients) of the 57 
available studies. In addition, given that many studies were based on National Registers data, the origin of 58 
the 1HPT diagnosis was not reported. This is of utmost importance, since 1HPT is often asymptomatic and 59 
its diagnosis is frequently made in the context of routine exams. Therefore, it is not possible to exclude that 60 
the increased 1HPT prevalence, that has been described among patients with cancer in some studies, could 61 
have been related, in fact, to the  increased number of biochemical investigations routinely performed in 62 
patients with neoplasia. Finally, a complete characterization of 1HPT patients regarding their disease 63 
activity, comorbidities and risk factors for cancer was lacking in all available studies, rendering the results 64 
scarcely comparable. 65 
Page 3 of 22
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
4 
 
In order to overcome these pitfalls, we designed a study for comparing the occurrence of malignant 66 
neoplasia in patients referred to our “Osteoporosis and Metabolic Disease” outpatient clinic and subsequently 67 
diagnosed with or without 1HPT. 68 
 69 
Design of the study, patients and methods 70 
Design of the Study and patients 71 
All Caucasian patients (n=1750, 1532 females, 218 males) referred to the “Osteoporosis and 72 
Metabolic Disease” tertiary care outpatient clinic since May 1st, 2014 to May 31st 2016 at Fondazione IRCCS 73 
Cà Granda-Ospedale Maggiore Policlinico in Milan (Italy), for the first report of osteoporosis and/or fragility 74 
fracture and/or increased calcium and/or PTH levels were considered eligible for the study. Since patients 75 
affected with osteoporosis may be referred to our outpatient clinic (a tertiary care center for the study of 76 
hyperparathyroidism and severe osteoporosis) even for the skeletal consequences of systemic diseases (20), 77 
some of which could per se influence the cancer risk, the study protocol was designed in order to avoid the 78 
foreseeable potential selection bias. Therefore it comprised the following exclusion criteria: I) the  finding of 79 
osteoporosis and/or fragility fracture and/or increased calcium and/or PTH levels in the context of 80 
investigations for the staging or follow-up of malignancy; II) the patients’ addressing for the need of the 81 
prescription of a bone-active drug in the context of aromatase inhibitors therapy, as recommended by our 82 
National Guidelines (21); III) the presence of neoplasia in the context of a previously identified familiar 83 
and/or hereditary syndrome (i.e. multiple endocrine neoplasia, hereditary breast or ovarian cancer) (22); IV) 84 
the presence of diabetes, obesity (i.e body mass index, BMI, ≥ 30 kg/m2), chronic liver diseases or other 85 
chronic disorders (i.e renal and hepatic transplant, chronic inflammation diseases) and/or substances and 86 
therapies (i.e glucocorticoids, immunosuppressants, alcohol abuse, external radiation) known to increase the 87 
cancer risk and/or calcium-phosphorous metabolism (23); V) the presence of heavy smoking habit (≥ 1 88 
pack/day) (24). On the basis of these criteria, 144 patients (n=6, n=6, n=20, n=97 and n=15 fulfilling the 89 
criteria I, II, III, IV and V, respectively) did not entry the study, and eventually 1606 patients (1407 females, 90 
199 males) were enrolled (Figure 1) 91 
From all patients, the occurrence of malignant neoplasia during the 10 years prior the study inclusion 92 
was recorded. The diagnosis of cancer have been ascertained by verifying the medical reports. This length of 93 
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observational period of time has been decided since in 1HPT patients the diagnostic delay may be even of 10 94 
years (25). In addition, from all patients we obtained information regarding the occurrence of fragility 95 
fractures (at spine, ribs, wrist, hip, and proximal humerus), cardiovascular events (i.e. myocardial infarction, 96 
stroke, transient ischemic attack, angina pectoris, pulmonary embolism, intracerebral hemorrhage, peripheral 97 
artery disease), hypertension and dyslipidemia during the 10 years prior the study inclusion. In all patients 98 
the diagnosis of osteoporosis or osteopenia was done on the basis of a dual X-ray absorptiometry (DXA) 99 
bone mineral density (BMD) assessment and/or of the occurrence of a fragility fracture (26, 27). Subjects 100 
were considered current smokers if they smoked more than 5 cigarettes/day and/or 10 packs/year (28).  101 
All patients underwent the biochemical testing for osteoporosis suggested by both the protocol 102 
approved in our Centre (20) and our national Guidelines (29), including, in particular, serum calcium, 103 
albumin, phosphorous, creatinine, PTH, 25hydroxy-cholecalciferol (25OHVitD), 24-h urine calcium and 104 
creatinine excretion levels. All patients with increased albumin-adjusted serum calcium levels, confirmed at 105 
least twice, were tested for ionized serum calcium levels. Primary hyperparathyroidism was diagnosed in the 106 
presence of hypercalcemia and elevated or inappropriately normal PTH levels, after the evaluation of 107 
calcium clearance:creatinine clearance ratio, in order to rule out familial hypocalciuric hypercalcemia (30). 108 
Eventually 163 patients (148 females, 15 males) were found to be affected with 1HPT while 1443 (1259 109 
females and 184 males) were not and were used as control group. 110 
 We reviewed the medical records preceding the study entry of all 1HPT patients. In 40 patients (37 111 
females, 3 male, age 70.7±11.3 years) we found that the hypercalcemia was already present at least 5 years 112 
before the enrolment.  In this subgroup of 1HPT patients we assessed the occurrence of malignancies during 113 
the period of time between the first finding of hypercalcemia and the study entry. These data were compared 114 
with those of 120 age-, and gender-matched subjects without 1HPT, who had been randomly selected from 115 
the whole group of control subjects. 116 
The study complies with the Declaration of Helsinki and it has been approved by the Ethical 117 
Committee of Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico, Milan, Italy. An informed 118 
consent has been obtained from each patient. 119 
 120 
 121 
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Methods 122 
Serum and urinary calcium, albumin, and phosphate were measured by standard colorimetric 123 
techniques. Total calcium was corrected for serum albumin according to the formula: total calcium 124 
(mg/dL)+(4.4−albumin (mg/dL))*0.8 (31) (reference interval 8.4–10.2 mg/dl). Serum intact PTH levels were 125 
measured by a two-step automated sandwich chemiluminescent immunoassay (DiaSorin), with intra- and 126 
interassay coefficients of variation <10% (reference interval 6.5– 36.8 pg/mL). The serum 25OHVitD 127 
concentration was measured by radioimmunoassay (Diasorin), with intra and interassay of 7.2% and <12%, 128 
respectively (normal levels above 30 ng/mL).  129 
Data regarding BMD were obtained by DXA scans at the spine and hip, performed  at our Hospital 130 
(Hologic Discovery, Waltham MA, USA) at lumbar spine (LS; in vivo precision 1.0%), total femur (FT, in 131 
vivo precision 1.7%) and femoral neck (FN, in vivo precision 1.8%) in the 77% of patients and at other 132 
centers (Hologic Discovery and Lunar GE) in the 23% of patients. Conventional spinal radiographs in lateral 133 
and anteroposterior projection (T4–L4) were obtained at baseline in all subjects with standardized technique. 134 
Vertebral fractures were diagnosed on visual inspection using the semiquantitative visual assessment 135 
previously described by Genant and coauthors. (32). 136 
 137 
Statistical analysis 138 
Statistical analysis was performed by SPSS version 21.0 statistical package (SPSS, Inc.). The normality of 139 
distribution was checked by Kolmogorov–Smirnov test. The results are expressed as mean±standard 140 
deviation if not differently specified. The comparison of continuous variables between patients with and 141 
without 1HPT was performed using Student’s t-test or Mann–Whitney U test, as appropriate. The categorical 142 
variables were compared by χ
2
 test.  143 
The logistic regression analysis assessed the association between the 1HPT diagnosis and the presence of all 144 
neoplasia and of the neoplasia that were significantly more frequent in 1HPT patients than in controls, after 145 
adjusting for variables that might influence the cancer risk, such as, age, gender (as appropriate), low 146 
25OHVitD levels and smoking habit.  147 
Values of p<0.05 were considered significant.  148 
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Results 149 
The clinical characteristics of the whole sample of patients (n=1606) are reported in table 1. During 150 
the 10 years prior the study entry, a malignant neoplasia occurred in 412 (26.2%) patients, with the breast, 151 
prostate and thyroid cancers being the most frequent ones. The other cancers occurred at colon, uterus, lung, 152 
kidney, skin, ovary, liver and pancreas in decreasing order. Breast and uterus cancer were reported only in 153 
female subjects. 154 
A condition of 1HPT was found in 163 patients, while 1443 patients were not affected with 1HPT 155 
(Figure 1). Among these latter, 47 patients showed a secondary hyperparathyroidism (i.e. elevated PTH in 156 
the presence of frankly normal calcium levels) due to hypovitaminosis D.  The comparisons between the 157 
clinical characteristics of patients with and without 1HPT are reported in table 2. Patients with and without 158 
1HPT were comparable as far as age, gender, prevalence of hypertension, cardiovascular events, 159 
dyslipidemia and osteopenia or osteoporosis was concerned. The fragility fracture prevalence and the 160 
smokers were significantly more prevalent among patients without 1HPT. As expected, in 1HPT patients 161 
serum and urinary calcium, total alkaline phosphatase and PTH levels were higher, while phosphorous and 162 
25OHVitD lower, than in patients without 1HPT. In 1HPT patients the overall occurrence of cancer and the 163 
occurrence of breast, kidney and skin cancer was significantly higher (1.7-, 1.8-, 8.3- and 6-fold increased, 164 
respectively) than in patients without 1HPT. For the other types of cancer a statistically significant difference 165 
was not found. 166 
The period of time between the study entry and the occurrence of neoplasia was lower in patients 167 
with 1HPT (56.3±23.1 months, range 36-116 months) than in those without 1HPT (89.0±33.6 months, range 168 
24-120 months). The prevalence of subjects in whom the neoplasia occurred at least 5 years before the study 169 
entry was higher in 1HPT patients (26/35, 74.3%) than in controls (40/179, 22.3%, p <0.0001). In the 40 170 
patients with 1HPT, in whom the hypercalcemia was already evident within 5 years before the study entry, 171 
the occurrence of neoplasia during this period of time tended to be higher (9/40 cases, 22.5%) than that in the 172 
120 subjects without 1HPT randomly selected as controls (14/120 cases, 11.7%, p=0.06).  173 
The logistic regression analysis showed that the occurrence of all neoplasia and of breast, skin and 174 
kidney neoplasia was significantly associated with the condition of 1HPT even after adjusting for age, 175 
gender (only for all cancers and skin cancer), smoking habit and hypovitaminosis D (table 3). Finally, in the 176 
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47 patients with secondary hyperparathyroidism, the prevalence of all cancers was comparable with that of 177 
patients with normal PTH levels (12.8% vs 12.4%) and reduced as compared with 1HPT patients (12.8% vs 178 
21.5%, p=0.005).  179 
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Discussion 180 
The present study shows that the occurrence of cancer, and in particular of breast, skin and kidney 181 
cancer is increased during the 10 years before the diagnosis of 1HPT even after adjusting for possible 182 
confounders such as age, gender, presence of hypovitaminosis D and smoking habit. 183 
The previous studies investigating the occurrence of neoplastic diseases in 1HPT gave discordant 184 
results. Indeed, while some data suggested that the 1HPT condition could be associated with an increased 185 
risk of breast, skin, colon, thyroid and kidney cancer (10-16), others did not (17, 18). The limits of these 186 
investigations were related to their retrospective design and to the fact that the origin of the 1HPT and cancer 187 
diagnoses was not clearly reported. Therefore, the 1HPT diagnosis could have been done in the context of 188 
cancer staging or, viceversa, cancer diagnosis in the context of 1HPT workup. To overcome these pitfalls, in 189 
some of these studies the neoplasia that had occurred before the 1HPT diagnosis were excluded (11, 13). 190 
This, however, could have introduced a further bias, since in 1HPT patients the diagnostic delay may be even 191 
of 10 years (25).  Finally, in all previous studies a complete characterization of subjects with and without 192 
1HPT regarding their comorbidities and risk factors for cancer was lacking, rendering  the finding of an 193 
increased cancer risk in 1HPT not clearly demonstrated. 194 
The design of the present study consented us to overcome most of these pitfalls. Indeed, the 195 
inclusion criteria (i.e. the referral to our “Osteoporosis and Metabolic Disease” outpatient clinic) have been 196 
the same for patients with and without 1HPT. By excluding patients with the finding of osteoporosis and/or 197 
fragility fracture and/or increased calcium and/or PTH levels in the context of investigations for the staging 198 
or follow-up of malignancy, we avoided the risk that an increased 1HPT finding in patients with cancer 199 
could have been due to the increased number of exams performed in these patients. Similarly, the exclusion 200 
of patients with  heavy smoking habit, diabetes, obesity and chronic disorders and/or therapies known to 201 
increase the cancer risk consented to avoid that a different occurrence of cancer in patients with and without 202 
1HPT could be related to the different healthy status of the subjects included in the study. 203 
In the present study the independent association between the all cancer occurrence and the female 204 
gender is probably related to high frequency of breast cancer. The high prevalence of 1HPT patients and the 205 
increased prevalence of smokers and of fractured patients among patients without 1HPT is not surprising. 206 
Indeed, in our tertiary care outpatient clinic patients are referred by their general practitioners generally for 207 
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an inadequate response to a bone-active drug and/or for the occurrence of a fragility fracture, which are both 208 
associated with the smoking habit (33), or for high calcium and/or PTH levels, while rarely for densitometric 209 
osteoporosis as unique reason. On the other hand, the finding that the prevalence of hypertension, 210 
dyslipidemia and cardiovascular events was comparable between patients with and without 1HPT somewhat 211 
confirms that the healthy status was similar between the two groups of patients. Therefore, in the absence of 212 
these possible confounding factors, the present study strongly suggests that the condition of 1HPT is 213 
associated with an increased occurrence of cancer, and, in particular, of breast, skin and kidney cancer, 214 
during the 10 years before the 1HPT diagnosis. 215 
It is evident, however, that the cross-sectional design of the present study does not consent to draw 216 
conclusions about causality. In addition, we have no certain information about the temporal distance between 217 
the onset of the parathyroid disease and the appearance of the malignancy. However, in 1HPT patients the 218 
period of time between the diagnosis of cancer and of 1HPT was lower than in subjects without 1HPT and, at 219 
variance with these latter, in the majority of 1HPT patients the neoplasia occurred less than five years before 220 
the 1HPT diagnosis (Figure 2). Importantly, in the subgroup of 1HPT patients, in whom the hypercalcemia 221 
was already evident at least 5 years before the study entry, the occurrence of neoplasia during this period of 222 
time tended to be higher than in controls. Overall these findings are in keeping with the hypothesis of a 223 
relationship between the cancer and the 1HPT occurrence. 224 
However, the possible role, if any, of PTH in the cancer development remains unclear.  The fact that 225 
the cancer risk may persist even after the recovery from 1HPT is against the hypothesis of a causative role of 226 
the PTH excess in the cancer pathogenesis (13). In keeping, in the present study we found that patients with 227 
secondary hyperparathyroidism (i.e. with increased PTH levels together with normal calcium levels) did not 228 
show an increased occurrence of neoplasia as compared with patients with normal PTH and calcium levels. 229 
Even if we have no information regarding the length of the secondary hyperparathyroidism, that could have 230 
influenced the results, this finding is in keeping with a previous study suggesting that patients with secondary 231 
hyperparathyroidism had an insignificant overall cancer risk (11). In addition, a previous study suggested a 232 
possible role of the increased calcium level, in the breast cancer development (34). Overall, these data 233 
suggest that in 1HPT the increased calcium levels, rather than PTH levels, may act as a contributor in the 234 
cancer pathogenesis.  235 
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A limit of the present study is related to the lack of reliable data on the vitamin D status during the 236 
10 years prior to diagnosis and even at the time of the study inclusion. Indeed, since our patients were mainly 237 
referred to our tertiary care center for osteoporosis and/or fragility fractures, we could not exclude that some 238 
of them were taking vitamin D supplements at the time of the diagnosis. This could explain the relatively low 239 
prevalence of secondary hyperparathyroidism in our sample. The lack of reliable information on vitamin D 240 
status in the patients may be of importance since hypovitaminosis D is associated with an increased risk of 241 
neoplasia (35) and in the 1HPT condition the 25OHVitD levels are often reduced (1-4), as suggested even by 242 
the present study. Notwithstanding these considerations, the association between the 1HPT condition and the 243 
increased occurrence of neoplasia has been confirmed even after adjusting for the vitamin D status. 244 
A further possible explanation of the increased risk of neoplasia associated with 1HPT is that both 245 
these conditions could be related to the same genetic predisposition. For example, given the possible effect 246 
of vitamin D in influencing the cell proliferation, in particular at the parathyroid glands, it is not possible to 247 
exclude that vitamin D status and metabolism and some genetic polymorphic variations in vitamin D 248 
metabolism, may have played a role in inducing a predisposition to the development of both parathyroid and 249 
neoplastic cells (36). 250 
Finally, even if patients with the most common risk factors for cancer (i.e. alcohol abuse, cancer-251 
causing substances, chronic inflammation, immunosuppression, obesity, diabetes, radiation, tobacco abuse), 252 
have been excluded, there are a number of other factors that could influence the development of cancer (for 253 
example the dietary habits and the sun exposure), that have not been assessed. 254 
Notwithstanding these limitations, the present study strongly suggest that during the 10 years prior 255 
the diagnosis of a 1HPT condition the occurrence of neoplasia, and in particular of breast, kidney and skin 256 
cancer, is increased.  257 
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Legend to Figure 1 371 
Title: Design of the study 372 
Footnotes: Exclusion Criteria: 1) the  finding of osteoporosis and/or fragility fracture and/or increased 373 
calcium and/or PTH levels in the context of investigations for the staging or follow-up of malignancy; 2) the 374 
patients’ addressing for the need of the prescription of an antifracture drug in the context of aromatase 375 
inhibitors therapy; 3) the presence of neoplasia in the context of a previously identified familiar and/or 376 
hereditary syndrome; 4) the presence of diabetes, obesity, chronic liver diseases or other chronic disorders 377 
and/or therapies and/or substances (i.e. glucocorticoids, immunosuppressants, alcohol, external radiation) 378 
known to increase the cancer risk; 5) the presence of heavy smoking habit (≥1 pack/day) 379 
 380 
Legend to Figure 2 381 
Title: Percentage of subjects with the occurrence of cancer within 5 years before the study entry among 382 
patients with cancer and primary hyperparathyroidism (1HPT) and controls with cancer. 383 
The neoplasia occurred within 5 years before the study entry in the 74.3% of 1HPT patients with cancer and 384 
in the 22.3% of non-1HPT patients with cancer (p <0.0001). 385 
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Table 1: Clinical characteristics of the whole sample of subjects included in the study  
The results are expressed as mean±SD or absolute number, with range or percentage in parentheses. 
1
myocardial infarction, stroke, transient ischemic attack, angina pectoris, pulmonary embolism, intracerebral 
hemorrhage, peripheral artery disease. 2Bone mineral density at any site expressed as T-score below -2.5 
and/or presence of fragility fractures.  
3
Bone mineral density at any site expressed as T-score between -1.0 
and -2.0. 4Clinical fragility fracture  spine, ribs, wrist, hip, and proximal humerus and/or morphometric 
vertebral fractures. 
5
Percentage in female patients. 
6
Percentage in male patients. Smoker: patient who smokes 
more than 5 cigarettes/day and/or 10 packs/year 
 All patients 
(n= 1606) 
Age (years) 65.4 ± 11.0 (42-93) 
Gender (females) 1407 (87.6) 
Hypertension 450 (28.0) 
Cardiovascular events
1
  110  (6.8) 
Dyslipidemia 233  (14.5) 
Osteporosis
2
 1375 (85.6) 
Osteopenia
3
 209 (13.0) 
Fragility fractures
4
 1103 (68.7) 
Smokers 308 (19.2) 
Calcium (mg/dL) 9.6 ± 0.6 (8.1-13.2) 
Phosporous (mg/dL) 3.5 ± 0.6 (1.9-4.8) 
Parathyroid hormone (pg/mL) 34.4 ± 41.3 (9.4-806.0) 
24-h urine calcium (mg/day) 196.4 ± 119.9 (60-980.0) 
25OHVitamin D (ng/mL) 41.3 ± 18.9 (2.0-133.0) 
All cancers 214 (13.3) 
Breast cancer
5 
 105 (7.5)
4 
Prostate cancer
6
 7 (3.5)
5 
Thyroid cancer 32 (2.0) 
Colon cancer 17 (1.1) 
Uterus cancer 13 (0.9) 
Lung Cancer 8 (0.5) 
Kidney Cancer 8 (0.5) 
Skin cancer 7 (0.4) 
Ovary cancer 4 (0.3)
4
 
Liver cancer 4 (0.2) 
Pancreas cancer  3 (0.2) 
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Table 2. Comparison between the clinical and biochemical characteristics and the prevalence of cancer in 
patients with 1HPT and without 1HPT 
The results are expressed as mean±SD or absolute number, with range or percentage in parentheses. 
1
myocardial infarction, stroke, transient ischemic attack, angina pectoris, pulmonary embolism, intracerebral 
hemorrhage, peripheral artery disease. 2Bone mineral density at any site expressed as T-score below -2.5 
and/or presence of fragility fractures.  
3
Bone mineral density at any site expressed as T-score between -1.0 
and -2.0. 4Clinical fragility fracture  spine, ribs, wrist, hip, and proximal humerus and/or morphometric 
vertebral fractures. 
5
Percentage in female patients. 
6
Percentage in male patients. Smoker: patient who smokes 
more than 5 cigarettes/day and/or 10 packs/year. 
 Patients with 1HPT 
(n=163) 
Patients without 1HPT 
(n=1443) 
p 
Age (years) 66.5 ± 12.4 (42-90) 65.2 ± 10.8 (42-93) 0.152 
Gender (females) 148 (90.8) 1259 (87.2) 0.192 
Hypertension 54 (33.1) 396 (27.4) 0.125 
Cardiovascular events
1
 15 (9.2) 95 (6.6) 0.210 
Dyslipidemia 20 (12.3) 213 (14.8) 0.392 
Osteporosis
2
 123 (75.5) 1252 (86.8)  0.875 
Osteopenia
3
 18 (11.0) 191 (13.2) 0.875 
Fragility fractures
4
 83 (50.9) 1020 (70.7) 0.001 
Smokers 10 (6.1) 298 (20.7) 0.001 
Calcium (mg/dL) 10.7 ± 0.6 (10-13.2) 9.5 ± 0.4 (8.1-10.4) 0.001 
Phosporous (mg/dL) 2.7 ± 0.5 (1.9-4.3) 3.6 ± 0.5 (2.7-4.8) 0.001 
Parathyroid hormone (pg/mL) 124.2 ± 85.5 (30.0-806.0) 24.3 ± 8.0 (9.4-134.0) 0.001 
24-h urine calcium (mg/day) 291.1 ± 157.5 (90.0-980.0) 185.5 ± 109.8 (60.0-975.0) 0.001 
25OHVitamin D (ng/mL) 36.2 ± 17.7 (4.0-88.0) 41.8 ± 18.9 (4.0-133.0) 0.001 
All cancers 35 (21.5) 179 (12.4) 0.001 
Breast cancer
5 
 18 (12.2) 87 (6.9) 0.021 
Prostate cancer
6
 0 (0.0) 7 (3.8) 1.000 
Thyroid cancer 6 (3.7) 26 (1.8) 0.104 
Colon cancer 1 (0.6) 12 (0.8) 1.000 
Uterus cancer 1 (0.7) 12 (1.0) 1.000 
Lung Cancer 2 (1.2) 6 (0.4) 0.191 
Kidney Cancer 4 (2.5) 4(0.3) 0.005 
Skin cancer 3 (1.8) 4(0.3) 0.026 
Ovary cancer 1(0.7) 3 (0.2) 0.359 
Liver cancer 0 (0.0) 4(0.3) 1.000 
Pancreas cancer  1 (0.6) 2 (0.1) 0.275 
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Table 3. Association between the presence of all cancer (panel A), skin cancer (panel B), kidney cancer 
(panel C) and breast cancer (panel D) with the presence of 1HPT, after adjusting for  hypovitaminosis, 
smoking habit, gender and age. 
 
1HPT: primary hyperparathyroidism. Smoker: patient who smokes more than 5 cigarettes/day and/or 10 
packs/year. Hypovitaminosis D: 25-hydroxy-vitamin D levels below 30 ng/mL 
 Odds ratio P value 95% CI 
Panel A: All Cancer    
Age (1 year increase) 1.029 0.000 (1.015-1.042) 
Female gender 1.837 0.031 (1.058-3.191) 
Hypovitaminosis D (yes) 1.354 0.082 (0.963-1.903) 
Smoker (yes) 1.066 0.742 (0.729-1.558) 
1HPT diagnosis (yes) 1.928 0.002 (1.270-2.929) 
Panel B: Skin Cancer    
Age (1 year increase) 1.013 0.682 (0.952-1.037) 
Female gender 1.387 0.765 (0.162-11.904) 
Hypovitaminosis D (yes) 3.368 0.270 (0.389-21.192) 
Smoker (yes) 1.012 0.991 (0.116-8.849) 
1HPT diagnosis (yes) 8.236 0.008 (1.717-39.509) 
Panel C: kidney cancer    
Age (1 year increase) 1.025 0.429 (0.964-1.091) 
Hypovitaminosis D (yes) 1.563 0.592 (0.306-7.981) 
Smoker (yes) 1.035 0.975 (0.120-8.928) 
1HPT diagnosis (yes) 9.184 0.003 (2.155-38.825) 
Panel D: Breast cancer    
Age (1 year increase) 1.024 0.013 (1.005-1.043) 
Hypovitaminosis D (yes) 1.432 0.139 (0.890-2.306) 
Smoker (yes) 1.153 0.590 (0.688-1.932) 
1HPT diagnosis (yes) 1.930 0.020 (1.112-3.352) 
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Figure 1: Design of the study  
Exclusion Criteria: 1) the  finding of osteoporosis and/or fragility fracture and/or increased calcium and/or 
PTH levels in the context of investigations for the staging or follow-up of malignancy; 2) the patients’ 
addressing for the need of the prescription of an antifracture drug in the context of aromatase inhibitors 
therapy; 3) the presence of neoplasia in the context of a previously identified familiar and/or hereditary 
syndrome; 4) the presence of diabetes, obesity, chronic liver diseases or other chronic disorders and/or 
therapies and/or substances (i.e. glucocorticoids, immunosuppressants, alcohol, external radiation) known 
to increase the cancer risk; 5) the presence of heavy smoking habit (≥1 pack/day)  
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Figure 2: Percentage of subjects with the occurrence of cancer within 5 years before the study entry among 
patients with cancer and primary hyperparathyroidism (1HPT) and controls with cancer.  
The neoplasia occurred within 5 years before the study entry in the 74.3% of 1HPT patients with cancer and 
in the 22.3% of non-1HPT patients with cancer (p <0.0001).  
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